ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CLGN / dividends
CUPR (21) RGNT (31) HSCS (38) LFWD (32) ⌘ Pro Terminal β†’

CollPlant Biotechnologies Ltd (CLGN) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.08 -1.33% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.06

CollPlant Biotechnologies Ltd (CLGN) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $11.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLGN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.08 (-1.33% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CLGN compare to CUPR and RGNT in the Health Care sector?
β–Ό

Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLGN?
β–Ό

Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.06 (-0.43%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (41/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510041
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D
Cash (8)Whales (9)SEC (11)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$24 Bull$4 Base$3 Bear
πŸ“¬ FREE CLGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CLGN)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
πŸ” WHY CLGN SCORES 41/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Whale & Options Positioning+9/20 pts (22% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
33
Grade E$3.91-0.8% Next Q
Q2 (-2Q)
36
Grade E$3.88+0.5% Next Q
Q3 (-1Q)
38
Grade E$3.90+4.6% Next Q
Current
41
Grade D-$4.08-7.2% Hist 90D Ξ±
Trajectory: E (33) β†’ D- (41)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CLGN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CLGN currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.74) and Max Pain ($4.28) forces dealer call-delta covering toward $24.04.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLGNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCLGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $45,269

Est. Year-10 Shareholder Yield: $815/yr
$11.6K
Yr 1
$13.5K
Yr 2
$15.7K
Yr 3
$18.3K
Yr 4
$21.3K
Yr 5
$24.7K
Yr 6
$28.8K
Yr 7
$33.5K
Yr 8
$38.9K
Yr 9
$45.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLGN)

  • βœ“Walkthrough of CLGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CLGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.39%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $4.40H $4.40L $4.08C $4.08VOL 44.3K
RES: $12.56SUP: $3.57SMA50: $3.74SMA200: $5.00
$17.78$13.68$9.57$5.47$1.37RES $12.56SUP $3.57$4.082026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CLGN Butterfly Map β†’ + Track CLGN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +360.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLGN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CLGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLGN)

Health Care Rank #450 of 1015 βš”οΈ CUPR vs CLGN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CLGN vs. CUPR, RGNT, HSCS, LFWD)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, CollPlant Biotechnologies Ltd (CLGN) ranks #450 by composite RQD confidence (41/100, grade D-) and #876 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, CLGN leads on earnings valuation at N/A trailing P/E, while CLGN leads on capital efficiency and profitability with -35.0% ROIC and 64.8% gross margin. CLGN currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLGN ACTIVE
CollPlant Biotechnologies Ltd
D- 41/100 β€” 64.8% -35.0% -1.33% $11.9M Benchmark Subject
CUPR
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 β€” -1.3% -35.0% +3.96% $13.5M /cupr-vs-clgn β†’
RGNT
Regentis Biomaterials Ltd.
E 31/100 β€” β€” -35.0% 0.00% $9.6M /rgnt-vs-clgn β†’
HSCS
HeartSciences Inc.
D- 38/100 β€” 59.1% -35.0% -9.67% $16.0M /hscs-vs-clgn β†’
LFWD
Lifeward Ltd.
E 32/100 β€” 96.0% -35.0% +1.82% $16.9M /lfwd-vs-clgn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001631487 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported GAAP revenue of $2.4M (+360.4% vs. FY2024 revenue of $515.0K , and -78.4% cumulative change since FY2023) , GAAP net income of -$11.5M, operating cash flow of -$9.4M, and free cash flow of -$9.4M (+35.2% YoY). On the balance sheet, CLGN closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.4M -$11.5M -$9.4M -$9.4M $10.8M β€”
FY2024 (FY) 2024-12-31 $515.0K -$16.6M -$14.1M -$14.6M $18.7M β€”
FY2023 (FY) 2023-12-31 $11.0M -$7.0M -$2.8M -$2.8M β€” β€”

3. CLGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.08 (-1.33% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.

How does CLGN compare to CUPR and RGNT in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLGN?

Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLGN trading relative to its 50-day, 200-day, and 52-week technical levels?

CLGN last traded at $4.08 (-1.33% on volume of 40,499 shares), positioning the stock +9.09% above its 50-day simple moving average ($3.74) and -18.40% below its 200-day simple moving average ($5.00). Across its 52-week range of $2.64 to $22.90, CLGN sits at the 7.1% percentile with a 14-day RSI of 54.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($3.57 to $4.59).

Direct Sub-Reports: CLGN RQD Cockpit CLGN 12M Forecast CLGN Earnings & Move CLGN Dividends & DRIP CLGN Insiders & 13F CLGN Whale Options CLGN Profit Sankey CLGN News & Why
ROARABLE RATING BRIEF β€’ RQD 41/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

CLGN β€” CollPlant Biotechnologies Ltd: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CollPlant Biotechnologies Ltd (CLGN) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.08 (-1.33% 1D, market capitalization $11.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 64.8%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CollPlant Biotechnologies Ltd (CLGN) is listed on NASDAQ and classified under the Health Care sector and Industrial Specialties industry,. Reported revenue was $2.4M in FY 2025, $0.5M in FY 2024, and $11.0M in FY 2023. Gross margin is reported at 64.8%, while operating margin is -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported $2.4M in annual revenue (up from $515.0K in FY2024, +360.4% YoY) and -$11.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.0M revenue, -$7.0M net income) through FY2025, CLGN scaled operating cash flow to -$9.4M and free cash flow to -$9.4M, backed by $10.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.64 – $22.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level information is the classification as Health Care / Industrial Specialties. Investors should treat the absence of mapped supply-chain links as a gap in the analysis rather than evidence of independence.

  • Key Question #1: Can CLGN sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.4M and free cash flow of -$9.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CollPlant Biotechnologies Ltd (CLGN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CLGN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLGN Bull vs. Bear Conversation Board β€” What's Your Call at $4.08?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLGN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $5.13 (+23.9%)
πŸ“Œ Pinned Debate

Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%

Here is why I am bullish on CLGN here at $4.14: Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%.. Compare CLGN's -60.0% operating margin and -35.0% ROIC against the rest of Industrial Specialties. As long as cash conversion holds up, dips toward $3.93 are getting bought.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” CLGN's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.39 (-18.1%)
Spot @ $4.14

Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a

Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a $3.7M private placement and exhausted offering capacity.. Look at the math on CLGN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $3.64 before getting long.

LIVE TAPE